MODD — Modular Medical, Inc.

Is MODD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of October 3, 2026

Modular Medical, Inc. (MODD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $2.03. The rating moved from Strong Oversold to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

Modular Medical, Inc. (MODD) is a small-cap medical device company with limited publicly available recent financial disclosure, making assessment of liquidity and runway uncertain. Macro risk-off sentiment, cooling appetite for device/digital-health IPOs, and payer/reimbursement pressures increase near-term downside susceptibility, while any regulatory approvals, commercialization progress, or partnership announcements would be the primary catalysts for meaningful upside. Given current market conditions, expect range-bound trading with elevated volatility and a high probability of dilution or financing risk absent clear positive developments.

Key factors

  • Limited public financial disclosure and no recent EDGAR comparison available, increasing uncertainty on cash runway and profitability.
  • Small-cap device exposure with potential sensitivity to IPO/window cooling and risk-off market conditions that suppress demand for healthcare/device stories.
  • Market-wide defensive flows and light volumes reduce near-term conviction and increase volatility risk for low-liquidity names.
  • Potential upside from successful regulatory milestones, commercialization progress or strategic partnerships/licensing.
  • Payer/reimbursement dynamics (including Medicare negotiation and Medicare Advantage shifts) can materially affect addressable market and pricing.
  • Supply-chain and manufacturing execution risks remain relevant given broader global supply-chain uncertainty.
  • Competitive pressures in medical devices and adjacent digital-health hybrids could compress share and pricing if differentiation is unclear.

Risks

  • No recent EDGAR filing comparison available — material uncertainty around cash runway, revenues, and operating burn.
  • Low liquidity and small-float dynamics can create outsized price swings and difficulty executing trades at scale.
  • Macro risk-off environment and IPO cooling for device/digital-health names can limit new investor demand and secondary financing options.
  • Regulatory or clinical setbacks, delays, or negative data could sharply impair valuation and commercialization timelines.
  • Adverse payer actions or unfavorable reimbursement rules (including Medicare negotiation outcomes) could reduce pricing power and market access.
  • Supply-chain disruptions or component shortages could delay product launches and increase costs.
  • Capital-raising/dilution risk if cash needs require equity financing under unfavorable market conditions.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MODD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.